tbuckley/cabot-search huggingface dataset:
Empowered to stop smoking: The impact of a SDT smoking cessation intervention on economically disadvantaged whites and blacks
Authors: C. D. Figueroa-Moseley, G. C. Williams, G. R. Morrow, P. Jean-Pierre, J. Carroll, J. Ryan
Journal: Journal of Clinical Oncology (2006)

1012 Background: Few studies have examined the potential influence of an empowering Self Determination Theory (SDT) intervention on reducing smoking behaviors and outcomes for Whites and Blacks. Objectives: To determine if empowerment to stop smoking is associated with smoking outcomes in Whites and Blacks, and to examine if empowerment to stop smoking improved under the SDT Intervention vs. Usual Care conditions. Methods: A longitudinal randomized trial study was conducted to examine the effect of a SDT and health behavior change intervention for tobacco cessation among adult smokers. Participants were randomized into the SDT Intervention or the Usual Care condition. The present study includes data from a sample of 821 Whites and 177 Blacks who completed anonymous surveys at 1, 6, and 18-months intervals on empowerment to stop smoking (Perceived Competence Scale, Treatment Self-Regulation Questionnaire), demographics, and smoking behaviors. Results: Stepwise logistic regressions showed that empowerment to stop smoking was associated with quitting smoking at 1, 6, and 18 month follow-up for both treatment conditions. At one month, participants in the SDT Intervention with the highest levels of empowerment were 6.3 times more likely to quit smoking as compared with those in the usual care condition who were only 3.15 times as likely to quit smoking. Similar findings were found at 6 months and at 18 months (6- month SDT Intervention Empowerment High: (OR = 8.66, 95% C.I. 4.6, 16.3); 6 month Usual Care Empowerment High: (OR = 3.10, 95% C.I. 1.4, 7.0); 18- month SDT Intervention Empowerment High: (OR = 4.10, 95% C.I. 2.2, 7.5); 18 month Usual Care Empowerment High: (OR = 3.11, 95% C.I. 1.3, 7.7). In the SDT Intervention at 6 months being Black increased successful quitting by 2.4 times. Conclusions: Findings indicate that at each time-point the SDT Intervention empowered more participants to stop smoking than usual care alone. Findings also suggest that Blacks may increase their ability to stop smoking in the SDT Intervention condition. These preliminary findings highlight the need to further investigate the possible roles of empowerment interventions in smoking cessation among Whites and Blacks, especially cancer patients. No significant financial relationships to disclose.
Single nucleotide polymorphism in IL1B is associated with infection risk in paediatric acute myeloid leukaemia
Authors: L. Sung, D. Dix, S. Cellot, B. Gillmeister, M.C. Ethier, N.M. Roslin, D.L. Johnston, J. Feusner, D. Mitchell, V. Lewis, R. Aplenc, R. Yanofsky, C. Portwine, V. Price, S. Zelcer, M. Silva, L. Bowes, B. Michon, K. Stobart, J. Traubici, U. Allen, J. Beyene, N. den Hollander, A.D. Paterson
Journal: Clinical Microbiology and Infection (2016)
Small-Molecule Inhibition of GCNT3 Disrupts Mucin Biosynthesis and Malignant Cellular Behaviors in Pancreatic Cancer
Authors: Chinthalapally V. Rao, Naveena B. Janakiram, Venkateshwar Madka, Gaurav Kumar, Edgar J. Scott, Gopal Pathuri, Taylor Bryant, Hannah Kutche, Yuting Zhang, Laura Biddick, Hariprasad Gali, Yan D. Zhao, Stan Lightfoot, Altaf Mohammed
Journal: Cancer Research (2016)

Abstract Pancreatic cancer is an aggressive neoplasm with almost uniform lethality and a 5-year survival rate of 7%. Several overexpressed mucins that impede drug delivery to pancreatic tumors have been therapeutically targeted, but enzymes involved in mucin biosynthesis have yet to be preclinically evaluated as potential targets. We used survival data from human patients with pancreatic cancer, next-generation sequencing of genetically engineered Kras-driven mouse pancreatic tumors and human pancreatic cancer cells to identify the novel core mucin-synthesizing enzyme GCNT3 (core 2 β-1,6 N-acetylglucosaminyltransferase). In mouse pancreatic cancer tumors, GCNT3 upregulation (103-fold; P &amp;lt; 0.0001) was correlated with increased expression of mucins (5 to 87-fold; P &amp;lt; 0.04–0.0003). Aberrant GCNT3 expression was also associated with increased mucin production, aggressive tumorigenesis, and reduced patient survival, and CRISPR-mediated knockout of GCNT3 in pancreatic cancer cells reduced proliferation and spheroid formation. Using in silico small molecular docking simulation approaches, we identified talniflumate as a novel inhibitor that selectively binds to GCNT3. In particular, docking predictions suggested that three notable hydrogen bonds between talniflumate and GCNT3 contribute to a docking affinity of −8.3 kcal/mol. Furthermore, talniflumate alone and in combination with low-dose gefitinib reduced GCNT3 expression, leading to the disrupted production of mucins in vivo and in vitro. Collectively, our findings suggest that targeting mucin biosynthesis through GCNT3 may improve drug responsiveness, warranting further development and investigation in preclinical models of pancreatic tumorigenesis. Cancer Res; 76(7); 1965–74. ©2016 AACR.
RETRACTED: Skin barrier impairment at birth predicts food allergy at 2 years of age
Authors: Maeve M Kelleher, Audrey Dunn-Galvin, Claire Gray, Deirdre M Murray, Mairead Kiely, Louise Kenny, W H Irwin McLean, Alan D Irvine, Jonathan O'B Hourihane
Journal: Journal of Allergy and Clinical Immunology (2016)
Sentinel lymph node molecular staging in head and neck squamous cell carcinoma
Authors: H. Goda, K. Nakashiro, T. Yoshimura, H. Nishikawa, T. Sumida, H. Wakisaka, N. Hato, M. Hyodo, H. Hamakawa
Journal: Journal of Clinical Oncology (2008)

17042 Background: Lymph node stage is an important prognostic factor in head and neck squamous cell carcinoma (HNSCC). Sentinel lymph node (SLN) biopsy has proven to be a valuable tool in determining the regional lymph node status. In this study, we have attempted to develop an efficient molecular biology-based SLN biopsy in HNSCC. Methods: A total of 212 lymph nodes (36 patients) resected on SLN biopsy for cN0 HNSCC (25 patients) or neck dissection for cN1/2 HNSCC (11 patients) were diagnosed by One Step Nucleic Acid Amplification (OSNA) method. OSNA has succeeded in developing a new technology that makes it possible to perform gene amplification within 30 minutes by eliminating a lengthy purification process. With this method, a lymph node is homogenized and put to direct gene amplification to detect metastasis. The site of the disease was tongue, gingiva, oral floor, buccal mucosa, and pharynx in 47% (17), 36% (13), 11% (4), 3% (1), and 3% (1), respectively. Each lymph node was divided into halves to diagnose metastasis. One of the half was used for the OSNA assay with cytokeratin 19 (CK19) and squamous cell carcinoma antigen (SCCA) mRNA, and the remaining block was subjected to semiserial sectioning, sliced at 200-μm intervals and then examined by H&E and cytokeratin AE1/AE3 immunohistochemical staining. A cut-off value of CK19 mRNA copy number was introduced, using a criteria defined for breast cancer. Results: Three of 25 patients with cN0 HNSCC were upstaged by SLN biopsy. Twenty-eight of 212 lymph nodes were histopathological positive. The sensitivity and specificity of OSNA assay with CK19 mRNA was 96.4% (27/28) and 97.3% (179/184), respectively. Furthermore, the OSNA assay with SCCA mRNA improved the specificity to 99.5% (183/184). An overall concordance rate between the OSNA assay and histopathology was 99.1%. The OSNA assay for SLN could be completed within 30 minutes. Conclusions: SLN biopsy for patients with cN0 HNSCC can modify staging and avoid unnecessary neck dissection. The OSNA assay showing high sensitivity and specificity can be used as a novel intraoperative detection tool of SLN metastasis in HNSCC patients. No significant financial relationships to disclose.
Aryl Hydrocarbon Hydroxylase and Epoxide Hydratase Activities: Age Effects in Mammary Epithelial Cells of Sprague-Dawley Rats&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN3"&gt;3&lt;/xref&gt;
Authors: J W Greiner, A H Bryan, L B Malan-Shibley, D H Janss
Journal: JNCI Journal of the National Cancer Institute (1980)

By use of techniques developed for rat mammary epithelial cell isolation, studies were conducted to characterize aryl hydrocarbon hydroxylase (AHH) and epoxide hydratase (EH) activities and to determine whether changes in the enzyme activities might contribute to the age-dependent changes in polycyclic aromatic hydrocarbon (PAH)-induced tumorigenesis in the rat mammary gland. Constitutive AHH and EH activities in rat mammary epithelial cell homogenates were substantially lower than those measured in liver (9,500×g) supernatant. The administration of 3-methylcholanthrene (MCA) or 7,12-dimethylbenz[a]anthracene increased mammary epithelial AHH activity 93- and 44-fold, respectively, whereas hepatic AHH levels rose 17- and 6-fold. Neither inducer had any effect on constitutive EH activity in either tissue. The addition (0.1 mM) of 7,8-benzoflavone (7,8-BF), SKF 525-A, or metyrapone to homogenates of mammary epithelial cells from MCA-treated rats inhibited AHH activity 93, 48, and 22%, respectively. In contrast, 7,8-BF addition decreased rat liver AHH activity 83%, whereas SKF 525-A and metyrapone had little effect. EH activities in rat liver and mammary epithelial cells were reduced with addition of 1,1,1-trichloro-2-propene oxide and cyclohexene oxide; however, trans-stilbene oxide had no effect in either tissue preparation. Additional studies determined the age-dependent changes in rat mammary epithelial AHH and EH activities. Constitutive AHH activity remained unchanged in rats between 40 and 100 days of age. In contrast, mammary epithelial EH activity was highest in 40-day-old Sprague-Dawley rats, declined in rats between 40 and 60 days of age, and remained constant in rats between 60 and 100 days of age. The level of MCA-induced AHH activity in rat mammary epithelial cell homogenates was age-dependent. MCA administration induced constitutive AHH activity 85- and 74-fold in mammary epithelial cells isolated from 50- and 60-day-old Sprague-Dawley females. The magnitude of mammary epithelial AHH induction was significantly lower in both younger and older animals. The results demonstrated PAH-metabolizing enzymes in rat mammary epithelial cells and suggested that the age-dependent incidence of mammary tumorigenesis may be attributed in part to the age-dependent inducibility of AHH activity.
P-0263 Prospective Study of Egfr Intron 1 CA Tandem Repeats as Predictive Factor of Benefit from Cetuximab and Irinotecan
Authors: Carlotta Antoniotti, Fotios Loupakis, Chiara Cremolini, Wu Zhang, Dongyun Yang, Takeru Wakatsuky, Marta Schirripa, Lisa Salvatore, Vincenzo Ricci, Francesco Graziano, Gianluca Masi, Melissa Janae Labonte, Yan Ning, Alfredo Falcone, Heinz Joseph Lenz
Journal: Annals of Oncology (2012)
Widespread RNA binding by chromatin-associated proteins
Authors: David G Hendrickson, David R. Kelley, Danielle Tenen, Bradley Bernstein, John L. Rinn
Journal: Genome biology (2016)

Recent evidence suggests that RNA interaction can regulate the activity and localization of chromatin-associated proteins. However, it is unknown if these observations are specialized instances for a few key RNAs and chromatin factors in specific contexts, or a general mechanism underlying the establishment of chromatin state and regulation of gene expression. Here, we perform formaldehyde RNA immunoprecipitation (fRIP-Seq) to survey the RNA associated with a panel of 24 chromatin regulators and traditional RNA binding proteins. For each protein that reproducibly bound measurable quantities of bulk RNA (90 % of the panel), we detect enrichment for hundreds to thousands of both noncoding and mRNA transcripts. For each protein, we find that the enriched sets of RNAs share distinct biochemical, functional, and chromatin properties. Thus, these data provide evidence for widespread specific and relevant RNA association across diverse classes of chromatin-modifying complexes.
A model to predict chemotherapy-related severe or febrile neutropenia in cycle one among breast cancer and lymphoma patients
Authors: V. A. Morrison, V. Caggiano, M. Fridman, D. J. Delgado
Journal: Journal of Clinical Oncology (2004)

8068 Background: Chemotherapy used to treat cancer may produce severe (absolute neutrophil count ≤250/mm3) or febrile neutropenia (SFN), which often results in fever, infection, and hospitalization. This can lead to dose delays or reductions in subsequent chemotherapy cycles and/or early termination of therapy. Recent studies suggest most patients who experience SFN do so early in the course of chemotherapy, in particular during the first cycle. Several recent risk models for neutropenia have identified baseline patient characteristics that predict the occurrence of neutropenia. The ability to identify patients at risk for developing neutropenia early in their therapy might help guide appropriate hematopoietic growth factor use. We evaluated possible risk factors associated with cycle 1 SFN among a sample of patients with NHL or breast cancer. Methods: A historical case series of 1,617 patients (704 NHL and 913 early-stage breast cancer) who received initial chemotherapy at 16 community and academic oncology practices between 1991 and 1999 were selected for study. SFN was defined as absolute neutrophil count ≤250/mm3 or febrile neutropenia. Results: A total of 461 patients (29%) experienced at least one SFN episode; 268 (58%) of these patients (167 [59%] with NHL and 101 [56%] with breast cancer) had SFN in cycle 1. Risk factors associated with cycle 1 SFN included age ≥65 years (Odds ratio [OR] 2.08; 95% CI: 1.48–2.92), baseline hemoglobin <12.0 g/dL (OR 1.90; 95% CI: 1.41–2.58), presence of heart, renal, or liver disease (OR 2.12; 95% CI: 1.03–4.36), NHL (OR 1.64; 95% CI: 1.16–2.32), planned full chemotherapy dose intensity (OR 2.74; 95% CI: 1.55–4.84), and no growth factor in the first 5 days of cycle 1 (OR 1.82; 95% CI 1.07–3.08). Conclusions: Data routinely available to the clinician can help identify patients at risk for SFN in cycle 1. In our model assessing chemotherapy-related SFN in breast cancer and lymphoma, patients ≥65 were twice as likely to have SFN in Cycle 1. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Amgen, Inc. Amgen, Inc.; Schering-Plough Amgen, Inc. Amgen, Inc.
Multi-institutional evaluation of sentinel lymph node (SLN) examination by one-step nucleic acid amplification (OSNA) assay in breast cancer: Performance of metastases detection and prediction of additional non-sentinel lymph node (non-SLN) involvement.
Authors: N. Sato, K. Honma, S. Noguchi, Y. Tamaki, H. Tsuda, T. Kinoshita, S. Nakamura, K. Tsugawa, K. Suzuki, M. Tsujimoto, K. Yoshidome, F. Akiyama, T. Iwase, D. Takabatake, R. Nishimura, K. Taniyama, H. Kato, S. Umemura, Y. Tokuda, T. Kamio
Journal: Journal of Clinical Oncology (2011)

1040 Background: Although sentinel lymph node biopsy (SLNB) is a common procedure in treatment of early stage breast cancer, SLN examination protocols have not been standardized. OSNA assay is a semi-automated lymph node examination method using molecular biological technique and has been valued as a tool for the intraoperative SLN examination with potential for standardization. Also, OSNA assay is quite unique in providing semi-quantitative result (++/+) reflecting volume of metastatic foci by measuring the amount of CK19mRNA in a lymph node. This study evaluated clinical utility of OSNA assay in the clinical setting at 10 institutes in Japan. Methods: 415 clinically node negative breast cancer patients scheduled for SLNB were enrolled. Each surgically-obtained SLN was applied to both postoperative pathological examination and OSNA assay; a central slice of each SLN with 1 mm thickness was applied to pathological examination for one section H&E staining, and the residual portion was applied to OSNA assay. For patients who received axillary dissection (ALND), non-SLN status was examined by routine method at each site. Results: OSNA showed significantly high number of positive patients over pathological examination (94 patients by OSNA assay vs. 67 patients by pathological examination). Among 35 patients who were judged as SLN positive only by OSNA assay, 32 patients received ALND and 6 (18.8%) of these patients had metastases in non-SLN. Among those who received ALND, 50 patients showed OSNA ++ and 34 patients OSNA +, with metastases in non-SLN in 22 patients and 6 patients respectively. Positive predictive value of OSNA ++ for non-SLN metastasis (22/50 = 44.0%) was significantly higher than that of OSNA + (6/34 = 17.6%) (p=0.01). Conclusions: These results suggest that OSNA assay can be more sensitive for detection of SLN metastases than pathological examination using one section H&E staining and semi-quantitative result of OSNA (++/+) defined by the amount of CK19mRNA can be a strong predictive factor of additional non-SLN involvement.
Spleen size for the prediction of clinical outcome in patients with primary sclerosing cholangitis
Authors: Hanno Ehlken, Raluca Wroblewski, Christophe Corpechot, Lionel Arrivé, Susanne Lezius, Johannes Hartl, Ulrike W Denzer, Ansgar W Lohse, Olivier Chazouilleres, Christoph Schramm
Journal: Gut (2016)

Dear Sir,

We read with interest the work of van der Meer et al 1 who propose a risk score for patients with chronic Hepatitis C. The authors demonstrate that the assessment of readily available and objective parameters can stratify patients according to the risk of disease progression. Patients with primary sclerosing cholangitis (PSC) usually develop progressive liver fibrosis and end-stage liver disease within 10–20 years.2 Simple and non-invasive means for disease stratification and prediction of prognosis are urgently needed. Indeed, the International PSC Study Group recently declared the research on surrogate end-point markers as a high-priority task,3 since several clinical studies investigating novel treatment strategies …
Epidemiology of acute promyelocytic leukemia in Italy
Authors: G. Avvisati, A. Mele, M.A. Stazi, M.L. Vegna, P. Pasquini, F. Mandelli, B. Rotoli, G. De Rosa, G. Papa, A. Venditti, P. Citarrella, M. Tambone Reyes, E. Ascari, R. Invernizzi, A. Cajozzo, M. Musso, A. Alberti, A. Peta, P. Rossi Ferrini, F. Leoni, F. Caronia, S. Mirto, F. Nobile, P. Iacopino, L. Resegotti, B. Allione, S. Monfardini, V. Zagonel, V. Liso, G. Specchia, S. Tura, G. Visani, G. Broccia, W. Deplano, F. Ricciuti, M. Pizzuti, M. Longinotti, S. Bonfigli, A. De Laurenzi, L. Pacilli, L. Deriu, A. Chierichini, B. Bizzi, G. Leone, R. De Biasi, E. Miraglia, L. Bruzzese, A. Abbadessa
Journal: Annals of Oncology (1991)
Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): A phase II study by the Cancer and Leukemia Group B (CALGB 30107)
Authors: T. M. Jahan, L. Gu, X. Wang, R. A. Kratzke, A. Z. Dudek, M. R. Green, E. E. Vokes, H. L. Kindler
Journal: Journal of Clinical Oncology (2006)

7081 Background: Targeting both vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) may be an appropriate therapeutic strategy in MM. MM express VEGF, PDGF, and their receptors, suggesting autocrine growth-stimulating loops. VEGF inhibitors and PDGF inhibitors have in vitro activity in MM. In MM patients (pts), high VEGF levels correlate with poor outcome. Vatalanib inhibits VEGF and PDGF receptor tyrosine kinases. Methods: We conducted a phase II trial of V in pts with unresectable, histologically-confirmed MM, measurable disease, no prior therapy, ECOG performance status (PS) 0–1. Primary endpoint: 3-month (mo) progression-free survival (PFS). V 1250 mg, was given orally daily. CT scans were obtained Q6 weeks. Baseline serum VEGF, PDGF were determined. Results: 47 eligible pts (46 evaluable) enrolled at 19 sites from 7/03–11/04. Pt characteristics: male 92%, median age 75 (range 51–92; 64% were &gt;70). Histology: epithelial 80%, sarcomatoid 11%, biphasic 9%. Site of origin: pleura 87%, peritoneum 6%, other 6%. PS 0/1: 21%/ 79%. 261 cycles were administered, median 3, range 1–32; 2 pts continue treatment. Grade 3/4 toxicities: neutropenia 2%, lymphopenia 2%, nausea/vomiting 15%/9%, increased ALT/AST 9%/6%, hypertension 2%, gastrointestinal bleed 2%. Partial response: 11% (5 pts), stable disease 66%. 3-mo PFS: 55% (95% CI: 40%, 68%), median PFS: 4.1 mo; median survival 10.0 mo. Median baseline serum levels in 40 pts: VEGF 425 pg/mL, PDGF 22754 pg/mL. There was no correlation between baseline VEGF or PDGF levels and response, PFS, or survival. Conclusions: The study did not achieve the protocol-specified 3-mo PFS of 75%. However, the objective response rate of 11% and median survival of 10 months are similar to other active single-agents for MM, which suggests that V may warrant further study in this disease. [Table: see text]
Lowered Superoxide Dismutase Activity in Distant Organs of Tumor-Bearing Mice&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN3"&gt;3&lt;/xref&gt;
Authors: S W Leuthauser, L W Oberley, T D Oberley, D P Loven
Journal: JNCI Journal of the National Cancer Institute (1984)

Solid tumors were induced by implantation of 5 X 10(6) Ehrlich carcinoma cells im into the right flank of 8- to 12-week-old female CBA/J mice. Tumor-bearing mice were killed at 0, 2, 4, 10, or 24 days after im implantation of the tumor cells, and superoxide dismutase (SOD) activities were determined in liver, spleen, kidneys, lungs, and leg muscle. Depressed SOD activities were seen in all organs studied. In liver, spleen, and kidneys, the manganese SOD (MnSOD) activities were depressed at some point after implantation, even though microscopic examination revealed no evidence of metastases in these organs. Cytochrome c oxidase activity was not diminished in any of the tissues studied, indicating that the decline in MnSOD was not due to a decline in the number of mitochondria or to a general decline in mitochondrial enzymes. When the tumor cells were dialyzed against 0.9% saline, the dialysate contained a factor that when injected im also inhibited SOD activity.
Stillbirths: recall to action in high-income countries
Authors: Vicki Flenady, Aleena M Wojcieszek, Philippa Middleton, David Ellwood, Jan Jaap Erwich, Michael Coory, T Yee Khong, Robert M Silver, Gordon C S Smith, Frances M Boyle, Joy E Lawn, Hannah Blencowe, Susannah Hopkins Leisher, Mechthild M Gross, Dell Horey, Lynn Farrales, Frank Bloomfield, Lesley McCowan, Stephanie J Brown, K S Joseph, Jennifer Zeitlin, Hanna E Reinebrant, Joanne Cacciatore, Claudia Ravaldi, Alfredo Vannacci, Jillian Cassidy, Paul Cassidy, Cindy Farquhar, Euan Wallace, Dimitrios Siassakos, Alexander E P Heazell, Claire Storey, Lynn Sadler, Scott Petersen, J Frederik Frøen, Robert L Goldenberg, Vicki Flenady, J Frederik Frøen, Mary V Kinney, Luc de Bernis, Joy E Lawn, Hannah Blencowe, Alexander Heazell, Susannah Hopkins Leisher, Jessica Ruidiaz, Andre Carvalho, Jane Dahlstrom, Christine East, Jane P Fox, Kristen Gibbons, Ibinabo Ibiebele, Sue Kildea, Glenn Gardener, Rohan Lourie, Patricia Wilson, Adrienne Gordon, Belinda Jennings, Alison Kent, Susan McDonald, Kelly Merchant, Jeremy Oats, Susan P Walker, Leanne Raven, Anne Schirmann, Francine de Montigny, Grace Guyon, Beatrice Blondel, Sabine de Wall, Sheelagh Bonham, Paul Corcoran, Mairie Cregan, Sarah Meany, Margaret Murphy, Stephanie Fukui, Sanne Gordijn, Fleurisca Korteweg, Robin Cronin, Vicki Mason, Vicki Culling, Anna Usynina, Karin Pettersson, Ingela Rådestad, Susanne van Gogh, Bia Bichara, Stephanie Bradley, Alison Ellis, Soo Downe, Elizabeth Draper, Brad Manktelow, Janet Scott, Lucy Smith, William Stones, Tina Lavender, Wes Duke, Ruth C Fretts, Katherine J Gold, Elizabeth McClure, Uma Reddy
Journal: The Lancet (2016)